EconPapers    
Economics at your fingertips  
 

Elevated nitric oxide during colitis restrains GM-CSF production in ILC3 cells via suppressing an AhR-Cyp4f13-NF-κB axis

Xingyu Zhao, Jun Li, Yime Zhang, Luni Hu, Di Wu, Jiayu Wu, Ruiqing Lyu, Peng Li, Gao An, Rongli Cui, Tao Sun, Pingping Zhu, Lin Bai, Changtao Jiang and Chao Zhong ()
Additional contact information
Xingyu Zhao: Peking University
Jun Li: Peking University Third Hospital
Yime Zhang: Peking University
Luni Hu: Peking University Health Science Center
Di Wu: Peking University Health Science Center
Jiayu Wu: Peking University
Ruiqing Lyu: Peking University
Peng Li: Peking University
Gao An: Peking University Health Science Center
Rongli Cui: Peking University Third Hospital
Tao Sun: Peking University Third Hospital
Pingping Zhu: Zhengzhou University
Lin Bai: Peking University
Changtao Jiang: Peking University
Chao Zhong: Peking University

Nature Communications, 2025, vol. 16, issue 1, 1-18

Abstract: Abstract Inflammatory bowel disease (IBD) presents a significant clinical challenge, yet the way bioactive gases are implicated remains elusive. We detect elevated colonic Nos2 levels in both IBD patients and mice undergoing diverse colitis. Additionally, Nos2 deficiency significantly aggravates anti-CD40-induced colitis, along with an increase in GM-CSF production by ILC3s. We identified a previously unappreciated role of the crucial ILC3 regulator, AhR, in promoting Cyp4f13 expression to allow ILC3s to bind with externally derived nitric oxide (NO). This further restrains Cyp4f13-catalyzed ROS generation and thereby diminishes NF-κB activation strictly necessary for GM-CSF production. Accordingly, the exacerbated anti-CD40-induced colitis due to defective NO generation in Nos2 deficient mice is efficiently recovered by a Cyp4f13 inhibitor, HET0016. Importantly, IBD patients with elevated NO binding to colonic ILC3s show decreased disease activity. Thus, our findings uncover a crucial regulatory mechanism for restraining colitogenic GM-CSF production in ILC3s and underscores its implication in IBD therapy.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-60969-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60969-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-60969-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-07-03
Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60969-x